Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7153964 | NOVARTIS | Pyrimidine compounds |
Feb, 2021
(3 years ago) | |
US8188276 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 3 months ago) | |
US8835430 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 3 months ago) | |
US9416112 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 3 months ago) | |
US9018204 | NOVARTIS | 2,4-pyrimidinediamine compounds and their uses |
Jan, 2023
(1 year, 3 months ago) | |
US7893074 | NOVARTIS | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2026
(1 year, 11 months from now) | |
US8399450 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(3 years from now) | |
US8039479 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Jun, 2030
(6 years from now) | |
US8039474 | NOVARTIS | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
Jun, 2030
(6 years from now) | |
US9309229 | NOVARTIS | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
Jan, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8377921 | NOVARTIS | Compounds and compositions as protein kinase inhibitors |
Nov, 2027
(3 years from now) | |
US8703787 | NOVARTIS | Methods of using ALK inhibitors |
Feb, 2032
(7 years from now) |
Zykadia is owned by Novartis.
Zykadia contains Ceritinib.
Zykadia has a total of 13 drug patents out of which 5 drug patents have expired.
Expired drug patents of Zykadia are:
Zykadia was authorised for market use on 18 March, 2019.
Zykadia is available in capsule;oral dosage forms.
Zykadia can be used as treatment of a cancer mediated by an anaplastic lymphoma kinase (alk).
Drug patent challenges can be filed against Zykadia from 29 April, 2018.
The generics of Zykadia are possible to be released after 02 February, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
ODE*(ODE*) | May 26, 2024 |
New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of a cancer mediated by an anaplastic lymphoma kinase (alk)
Dosage: CAPSULE;ORAL